A newly developed ester type oral cephem antibiotic T-2588, was investigated for its antibacterial activity, absorption, excretion, tissue penetration, placental penetration and clinical efficacy in the obstetric and gynecologic field, and the following results were obtained.
1) The MICs of T-2525 for 243 strains of 15 species o clinical, isolates were examined. They peaked at 1.56μg/ml in S.
... [Show full abstract] aureus, 0.78μg/ml in S. epidermidis, 0.2μg/ml in E. coli and K. pneurnoniae, 1.56μg/ml in S. marcescens, 0.78μg/ml in E. cloacae, ≥200μg/ml in C. freundii, ≥0.05μg/ml in Proteus sp., 0.2μg/ml in Peptostreptococcus sp. and Anaerobic streptococci.
2) Absorption & Excretion: The serum concentration of the drug reached the peak level of 0.67-1.3μg/ml at about 3-4 hours after oral administration, of 100mg and 1.75μg/ml after 200mg administration, and 31% of the drug was excreted into the urine within 8 hours.
3) Tissue penetration; Tissue penetration of the drug into intrapelvic genital organs was found to be good, the peak level in uterine arterial serum was 1.7μg/ml and tissue level was 1.09μg/g after oral administration of 200mg.
4) Placental penetration: The penetration of the drug into umbilical cord blood and amniotic fluid was measured following maternal administration and the peak level of the drug was 0.89μg/ml in the umbilical cord blood and 6.0μg/ml in the amniotic fluid.
5) Clinical results: T-2588 was given to 43 cases of obstetric and gynecologic infections with a daily dose of 300mg and 93% of clinical efficacy and 83% of bacteriological response were obtained. As to side effect, one case of elevation of GOT, GPT and BUN was observed.
From these findings, T-2588 was considered to be useful antibiotic agent in obstetric and gynecologic infections.